DBDeena Beasley

1. Article · Aug 4, 2026 · By Deena Beasley

   Amgen second-quarter sales rise 9%, profit tops Street view (opens the original)

   Excerpt · Neutral tone · English

   Read excerpt

   Aug 3 (Reuters) - Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop ‌experimental weight-loss drug MariTide. The California-based biotech said it has discontinued development of a different obesity candidate known ‌as AMG 513, which was in early-stage clinical testing. Amgen's second-quarter adjusted earnings rose 4% from a year earlier to $6.29 per share,

   Feedback

2. Article · Aug 4, 2026 · By Deena Beasley

   Gilead second-quarter sales rise 8%, beating Wall Street estimates (opens the original)

   Excerpt · English

   Read excerpt

   Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss ‌due to costs related to a series of acquisitions. The company's overall revenue rose 10% to $7.8 ‌billion, beating Wall Street expectations of $7.4 billion, according to LSEG data. Gilead cited strong sales of HIV products, cancer drug Trodelvy and ​liver disease drug Livdelzi for the results. "HIV sales grew 12%, reflecting cont

   Feedback

Last 90 days. Choose a month to open its work.

Named in the text we hold. One piece can cover several.

• Wall Street2 pieces
• Los Angeles1 piece
• Ouro Medicines1 piece
• Drug Administration1 piece